Goethe-University Frankfurt, Institute of Pharmaceutical Chemistry, Max-von-Laue-Str. 9, D-60438 Frankfurt/M., Germany.
Molecules. 2011 Dec 5;16(12):10013-28. doi: 10.3390/molecules161210013.
YS-121 [2-(4-chloro-6-(2,3-dimethylphenylamino)pyrimidin-2-ylthio)octanoic acid] is the result of target-oriented structural derivatization of pirinixic acid. It is a potent dual PPARα/γ-agonist, as well as a potent dual 5-LO/mPGES-1-inhibitor. Additionally, recent studies showed an anti-inflammatory efficacy in vivo. Because of its interference with many targets, YS-121 is a promising drug candidate for the treatment of inflammatory diseases. Ongoing preclinical studies will thus necessitate huge amounts of YS-121. To cope with those requirements, we have optimized the synthesis of YS-121. Surprisingly, we isolated and characterized byproducts during the resulting from nucleophilic aromatic substitution reactions by different tertiary alkylamines at a heteroaromatic halide. These amines should actually serve as assisting bases, because of their low nucleophilicity. This astonishing fact was not described in former publications concerning that type of reaction and, therefore, might be useful for further reaction improvement in general. Furthermore, we could develop a proposal for the mechanism of that byproduct formation.
YS-121[2-(4-氯-6-(2,3-二甲基苯基氨基)嘧啶-2-基硫代)辛酸]是吡嗪尼酸定向结构衍生的产物。它是一种有效的双重 PPARα/γ激动剂,也是一种有效的双重 5-LO/mPGES-1 抑制剂。此外,最近的研究表明其具有体内抗炎作用。由于其对多种靶点的干扰,YS-121 是治疗炎症性疾病的一种很有前途的候选药物。正在进行的临床前研究将因此需要大量的 YS-121。为了满足这些需求,我们优化了 YS-121 的合成。令人惊讶的是,我们从不同的叔烷基胺在杂芳基卤化物的亲核芳香取代反应中分离并表征了副产物。由于这些胺的亲核性较低,它们实际上应该作为辅助碱。这一惊人的事实在前人关于该类反应的出版物中没有描述,因此可能对一般的进一步反应改进有用。此外,我们可以提出该副产物形成的机制建议。